Abstract Library

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?

Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Yuan B, Chen Y, Zhang P, Wang X, Tan H,

Keywords: Pancreatic net, G1, G2, Ki-67, overall survival time,

#2831 Immunohistochemical Profile of Digestive Neuroendocrine Neoplasms: A Retrospective Analysis in a Single Algerian Institution

Introduction: Neuroendocrine Noplasms (NEN) are rare tumours, but their incidence is clearly increasing in our country due to the improvement of diagnostic means, in particular the generalization of immunohistochemical techniques. The digestive location represents more than 70% of the cases. The anatomopathological study enables to classify the NEN in different prognostic grades according to the degree of differentiation, mitotic index and Ki67.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belabdi D

Authors: Belabdi D, Mekarnia A, Ouzit S, Ainouche A, Oukkal M,

Keywords: Digestive neuroendocrine neoplasm, immunohistochemical profil, WHO classification 2017,

#2821 Nucleophosmin Expression and Relocation in Pancreatic Neuroendocrine Tumors: Preliminary Data

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms with unpredictable clinical course and biological behavior. Nucleophosmin (NPM) is an important multifunctional protein mainly located in the nucleolus. NPM has been reported to be overexpressed in many types of human cancer, activating tumor development and progression. However, the role of NPM in PanNETs is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Delektorskaya V, Bukaeva I, Ponomareva M, Smirnova E,

Keywords: neuroendocrine tumor, pancreas, nucleophosmin, immunohistochemistry, prognosis,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,

#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status

Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt K,

Keywords: nutritional status, malnutrition, chemotherapy, somatostatin analogues, everolimus, NETG1/G2, survival,